GEN-MKT-18-7897-A
Jun 8, 2020 | Biopharma, Blogs, Pharma | 0 comments
There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000 clinical trials involving gene therapies or oligonucleotides currently in various stages, and 11 gene therapy drugs already on the market, it is clear the potential benefit to human health is profound.
This new generation of therapeutic modalities presents unprecedented technological challenges in bringing therapies to patients. These challenges have affected both the speed and ultimate cost of bringing new therapies to market, with many gene therapeutics now categorized as some of the most expensive medications currently in existence. Ultimately, there is a lack of sufficient tools as we seek faster and more accurate methods for characterizing these new classes of drugs.
Although faced with many unique challenges and still at its very early stages, the global gene therapy market is growing rapidly. As of 2019, the size of this market is estimated to be more than $1 billion, and it is expected to expand at a compound annual growth rate (CAGR) of 32%. This growth is primarily driven by an increase in the number of clinical trials, the amount of government and private funding and the number of partnerships between small biotech and large pharmaceutical companies.
This type of growth brings many opportunities, and to take advantage of them, it is crucial that you are prepared with solutions to the challenges ahead. To help you succeed, we invite you to download a copy of the gene therapy and oligonucleotide compendium. This compendium was created with you in mind, and it aims to provide you with precision analytics that will help bring your therapies to market faster.
The compendium includes:
Download now >
For more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.
PFAS are increasingly at the center of regulatory change, scientific research, and industry discussion worldwide. As analytical capabilities improve and expectations around environmental responsibility continue to evolve, understanding the role PFAS play, and how they are being addressed, has never been more important. This blog provides an overview of what PFAS are, why they matter, and how responses from regulators and industry are changing.
Pesticides are widely used in agriculture to protect crops and maintain yield, but their presence in food must be carefully monitored. To safeguard consumers, regulatory authorities worldwide set maximum residue limits (MRLs), often at very low concentrations and across a wide range of compound classes.
Posted by
You must be logged in to post a comment.
Share this post with your network